$1.46
+0.00 (+0.00%)
Open$1.46
Previous Close$1.46
Day High$1.46
Day Low$1.41
52W High$4.07
52W Low$0.81
Volume—
Avg Volume68.8K
Market Cap23.68M
P/E Ratio—
EPS$-0.90
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,014.4% upside
Current
$1.46
$1.46
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.76M | 5.13M | 3.86M |
| Net Income | -12,883,873 | -15,821,374 | -155,305 |
| Profit Margin | -343.0% | -325.8% | -4.0% |
| EBITDA | -13,529,283 | -17,536,933 | -205,551 |
| Free Cash Flow | — | — | -168,121 |
| Rev Growth | -26.7% | -26.7% | +19.6% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |